/term/insider-ownership/FRA:978 Adagene (FRA:978) Insider Ownership
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Insider Ownership

Adagene (FRA:978) Insider Ownership : 0.00 % (As of Jun. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Adagene Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adagene's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adagene's Institutional Ownership is 0.02%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adagene's Float Percentage Of Total Shares Outstanding is 0.00%.


Adagene Insider Ownership Historical Data

The historical data trend for Adagene's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Insider Ownership Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
Get a 7-Day Free Trial - - - - -

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adagene Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Adagene (FRA:978) Business Description

Traded in Other Exchanges
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene (FRA:978) Headlines

No Headlines